Extranodal NK/T Cell Lymphoma- Nasal type: Experience from an Indian regional cancer centre

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Lymphomas
Presenter Smitha Saldanha
Citation Annals of Oncology (2018) 29 (suppl_9): ix87-ix93. 10.1093/annonc/mdy437
Authors S.C. Saldanha, K. Govind Babu, D. Lokanatha, L.A. Jacob, M.C. Suresh Babu, K..N. Lokesh, A.H. Rudresha, L.K. Rajeev, G.V. Giri, P. Khandare
  • Department Of Medical Oncology, Kidwai Cancer Institute, 560029 - Bangalore/IN



Extranodal NK/T cell lymphoma- nasal type is an aggressive rare non-Hodgkin’s lymphoma subtype. It presents with the involvement of nasal and upper aerodigestive region causing extensive destruction of these midline structures. It has a predilection for Asian population. Most cases present in early stage disease. Treatment outcomes are usually poor and no consensus for optimal treatment strategy exists.


This is a retrospective study of Extranodal NK/T cell lymphoma- nasal type, diagnosed in a regional cancer centre in India during the period of 2012 to 2017. The demographic and clinical features, laboratory parameters, radiological, histo-pathological features and outcomes with treatment were studied. Patients were treated with SMILE or AspaMetDex regimens sandwiched with radiotherapy.


All patients presented with clinical features of nasal obstruction, either with nasal stuffiness or difficulty breathing through nose. The median duration of symptoms was 3 months (range, 1–6 months). One patient had palatal perforation at presentation while two others developed during treatment. None of the patients had palpable peripheral lymphadenopathy or hepatosplenomegaly. B symptoms were not reported by any patient. Out of nine patients, eight received treatment. At a median follow up of 18 months (10-36 months), six of the eight patients have completed treatment and are in complete remission. The other two are currently undergoing treatment. Five of six patients receiving SMILE regimen had at least one episode of grade 4 febrile neutropenia and grade 4 thrombocytopenia was reported in one patient. Patients receiving AspaMetDex did not have any grade 3/4 hematological toxicity. No recurrences or deaths were reported during treatment or follow up. Median OS was not reached.


Extranodal NK/T cell lymphoma- nasal type is rare aggressive NHL subtype with good response to L-asparginase based chemotherapy sandwiched with RT with good tolerability and manageable toxicity profile.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Kidwai Cancer Institute, Department of Medical Oncology.


Has not received any funding.


All authors have declared no conflicts of interest.